IBM Research to collaborate with Melanoma Institute Australia

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

IBM Research will undertake research with Melanoma Institute Australia to help further advance the identification of melanoma using cognitive technology.

This research builds on IBM’s existing research agreement with MoleMap, which uses advanced visual analytics to analyze more than 40,000 data sets including images and text. IBM Research plans to analyze dermatological images of skin lesions to help identify specific clinical patterns in the early stages of melanoma. The Australian research team aims to help reduce unnecessary biopsies and help clinicians more accurately understand skin cancer, which could help to improve patient care.

YOU MAY BE INTERESTED IN

Candace S. Johnson leads America’s oldest cancer research center and Jonathan W. Friedberg leads the newest NCI-designated center. Their catchment areas are contiguous, their faculty and staff members collaborate often, and together their institutions embody the culture of NCI-designated cancer centers. 

In the first meeting of the National Cancer Advisory Board since the inauguration of President Donald Trump, NCI Principal Deputy Director Douglas R. Lowy addressed many of the burning questions the oncology field has for the institute. On indirect costs: NCI will continue to use previously negotiated and approved indirect cost rates, with the exception...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login